LBF20406LT08: Difference between revisions
No edit summary |
No edit summary |
||
(9 intermediate revisions by the same user not shown) | |||
Line 6: | Line 6: | ||
|LipidBank=XPR3117 | |LipidBank=XPR3117 | ||
|LipidMaps=LMFA03020015 | |LipidMaps=LMFA03020015 | ||
|SysName=5S,12S- | |SysName=(5S,12S) -Dihydroxy- (cis-6,trans-8,trans-10,cis-14) -eicosatetraenoic acid | ||
|Common Name=&&12-epi Leukotriene | |Common Name=&&12-epi Leukotriene B_4&&(5S,12S) -Dihydroxy- (6Z,8E,10E,14Z) -eicosatetraenoic acid&& | ||
|Source= | |Source= | ||
|Chemical Synthesis= | |Chemical Synthesis= | ||
|Metabolism= | |Metabolism= | ||
|Biological Activity=12-epi LTB4 has a week agonistic character at both recombinant human BLT1 and BLT2 approximately 10 _M for complete activation.[[Reference:Yokomizo_T:Kato_K:Hagiya_H:Izumi_T:Shimizu_T:,J. Biol. Chem.,2001,276,12454|{{RelationTable/GetFirstAuthor|Reference:Yokomizo_T:Kato_K:Hagiya_H:Izumi_T:Shimizu_T:,J. Biol. Chem.,2001,276,12454}}]] | |||
}} | }} | ||
{{Lipid/Footer}} | {{Lipid/Footer}} |
Latest revision as of 07:51, 21 October 2010
LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
IDs and Links | |
---|---|
LipidBank | XPR3117 |
LipidMaps | LMFA03020015 |
CAS | |
KEGG | {{{KEGG}}} |
KNApSAcK | {{{KNApSAcK}}} |
mol | LBF20406LT08 |
12-epi Leukotriene B4 | |
---|---|
Structural Information | |
(5S,12S) -Dihydroxy- (cis-6,trans-8,trans-10,cis-14) -eicosatetraenoic acid | |
| |
Formula | C20H32O4 |
Exact Mass | 336.23005951199997 |
Average Mass | 336.46567999999996 |
SMILES | C(CC=CC[C@@H](C=CC=CC=C[C@@H](CCCC(O)=O)O)O)CCC |
Physicochemical Information | |
12-epi LTB4 has a week agonistic character at both recombinant human BLT1 and BLT2 approximately 10 _M for complete activation. Yokomizo_T et al. | |
Spectral Information | |
Mass Spectra | |
UV Spectra | |
IR Spectra | |
NMR Spectra | |
Other Spectra | |
Chromatograms |
Reported Metabolites, References | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
|